Gene C. has ruined this stock with the last financing and then compounded that toxic deal by getting involved with a fleabag IR firm. Get used to this kind of action if you're going to hold this, penny traders rushing in and panicking out with every PR and "promotion" of the company. With each of these promotions they throw away enough money to build at least one LuViva unit. Brilliant move, no?
Confirmation that GTHP is in bed with lowlifes. I had to laugh when I saw one of these so called publications actually got the company name wrong...
Our New Pick Is Grabbing Headlines…
Great Plains Holdings, Inc. (symbol: GTHP)
If you are going to catch a company on its way up, then GTHP is the sort of company you want to catch.
The medical technology company has a very strong news profile which includes the recent closing of a deal worth $10 million.
GTHP is also engaging the FDA for approval of its LuViva Advanced Cervical Scan and recently presented a plan for advancing the pre-market approval (PMA) application.
There’s more on the FDA goodness below but know that at 6 cents a share there hasn’t been a better time to make a move on this company.
There’s considerable bounce opportunity which combined with the strong news could send GTHP on a huge run north.
You needn’t worry about entry and exit opportunities either: GTHP is experiencing very strong daily volatility providing us with significant windows.
It all makes for a great potential showing so make your move ASAP.
Check Out These 5 Key Short Term Technicals
1. GTHP has some of the strongest bounce potential we’ve seen in the medical technology play and is trading with a RSI of 30.
2. GTHP showcased its upside in July when in one session it delivered intraday gains of up to 27%. This after rallying to a high of .14.
3. GTHP recently announced second quarter 2015 financial results and confirmed a recent deal closed worth $10 million.
4. GTHP has seen daily volatility explode in recent weeks. Average volume of 565K recently gave way to a 1.2 million share breakout.
5. GTHP is trading below its 50 DMA of .11, suggesting potential undervaluation of up to 83% over the short term.
The predictions of immediate demise are a little silly given they have almost $2-million in cash on hand. They're not going to have an easy time though, IMO, finding non-dilutive financing given the lack of profit on the LuViva units in the Turkey order. The large holders on the BOD that Faupel could count on appear to be done throwing money at this, hence the painful toxic deal with Aquarius. Yes, .20 would be nice but this is something you play with your Vegas money at this point. GL.
punta, zero, gthp10bagger, etc., etc., etc. The serial board spammer returns. Haven't you done enough damage here?
Type "IRTH" in the field above and search all boards. Select "All" for timeframe. This isn't the kind of firm GTHP should be involved with. Have a nice day.
Dump and paint, been going on awhile. If today is any indication, this could easily blow down to .03 this week. Sad. Maybe it reverses with an order announcement from Kenya but, IMO, if IR engages in more shadowy activities any gains will be short lived again. This CEO has severe credibility issues at this point.
Another IRTH client "promotional campaign" - Rightscorp Inc. - via something called Penny Stock Tweeters. This is the IR firm that GTHP has hired. Where is the BOD? Are they in agreement that this is the kind of firm that GTHP should be involved with?
$RIHT – Rightscorp, Inc., promotional campaign starting Aug 12, 2015 @ 4:06 PM CST
August 12, 2015 Stock Promotion Tracking Tags: Penny Stock Tweeters, Rightscorp Inc., Rightscorp Inc. Penny Stock, Rightscorp Inc. Promo, Rightscorp Inc. Stock Quote, RIHT, RIHT Penny Stock, RIHT Promo, RIHT Stock Promotion, RIHT Stock Quote
Start time:4:06 PM
Start date:August 12, 2015
Stock promoter:"Penny Stock Tweeters"
Stock promoter rank:101 out of 141
Year of incorporation:-
Market capitalization:$12,765,292(as of August 11, 2015)
Business description:Business services, misc
This company can survive and thrive while saving lives, but not without new leadership.
A lot of good questions were asked during the conference call Q&A, everyone should listen to it. GTHP has made a technologically significant breakthrough in cervical cancer screening. Unfortunately, the current CEO is on track to run the company into the ground.
So it would appear that the Turkey order isn't going to make money. The 50-60% margin on disposables Gene C. stated just doesn't wash unless they have structured this deal to sell the units at a substantial loss in order to maintain the stated margin on disposables. This makes ZERO sense.The razor/blades model that arrived with this CEO is insane. A razor is a commodity, LuViva is a device that took years to develop that will save countless lives and save incalculable dollars in healthcare costs to countries adopting it. How do they justify giving it away at a loss?
The most glaring point of the flawed business model is that GC stated it will now take the sale of 250 devices per year to reach cash flow break-even. This is up from 120 devices that had been stated for years. And Gene could not state what the gross margin would be when they reach that production level. Given what the units were sold to Turkey for and the revelation that LuViva uses a number of custom parts whose cost will not decline as production ramps, margins will likely be non-existent to razor (pun intended) thin.
Even more disturbing was the revelation that the company will not have the cash to produce the units should a sizable order from Kenya come through. Gene says they are looking at non-dilutive financing possibilities but after the last deal it is apparent no one is knocking their door down. I doubt that changes given the lack of profit generated from the Turkey order.
Glad someone called Gene out on IR spending. We're selling units at a loss but we have money to spend with P&D publications so that warrant holders can convert and dump? Great call on that move. This company can achieve great things, but not with this CEO.
The company needs to provide some detail on the Turkey order tomorrow. The $10-million number seems low given the number of units involved and the previously stated selling prices. We need to know whether or not they are going to lose money on every LuViva unit they ship and what their margins on the disposables are when sold through a distributor.
" Load up before the flood gates open." Come back and post this when they announce new financing and have moved DMRJ/Platinum out of the picture. It would apply when that happens.
I certainly wasn't thinking 2017 when I got back into this. The third FDA rejection and subsequent massive dilution killed any thoughts I had of this being a home run. With a reverse split pretty much guaranteed now I'm really not prepared to throw any more money at this, especially when GTHP still doesn't make a dime in profit on the units. Your 2017 target might be ambitious unless they finally get FDA approval. GLTA.
It is what it is - the kind of financing you get when you're desperate for cash. At this point I would be delighted to just break even. Worst spec play ever.
No, maymay, you have me confused with ken and the pineapple who started this thread. You know me, I only buy on the dips. Okay, putting you back on ignore. Sleep tight.
I've done all the research on this company that I need to, skippy. Apparently the concept of shareholder value is lost on you. These people have failed on that count,. The company is sitting on a huge TSA contract and has the recent wins in Europe to their credit also and yet the stock is sitting at 78 cents today. Like McGann and Liscouski on the last conference call, you and the other pep squad posters on here ignore, and get irritated at even the mention of, the elephant in the room - the debt and the ongoing dilution. When this crew comes out and says it is a priority to get better terms on its financing and end the ongoing dilution and we're sitting at a share price more indicative of the recent contract wins, then they can start granting themselves these kind of numbers of options. Until then, I'll vote no. I'm not holding my breath though, not after the way Liscouski responded to a shareholder on the last call and then McGann said, "we gotta go" and ended the call. And now they want to increase the OS by 50,000,000 shares while offering no reason for the need to do that. Incredible.
It's very misleading of you to suggest that the current shareholder lawsuit is the reason for the current share price when it is obvious the ongoing dilution is the reason. The lawsuit was filed because the company was not in compliance with state law and only after they refused to respond to the shareholder's (Miller) repeated attempts to contact them. And by the way, the case is Miller v Bolduc, et al. Meaning Bolduc and others if you didn't know what that meant. Have a nice day.
If you're inclined to take whatever #$%$ you're handed and say 'thank you' then by all means vote yes. These people can get their options after they've earned them - and they haven't. Not when the share price has deteriorated to what it is today. And not when they send out a proxy with only one new outside director nominee on it. Not when they try to consolidate power to themselves with no one to keep them in check. If you don't like your money or any corporate governance in a company you own then go ahead and vote yes. I voted NO on every line, and one year on the exec compensation item. The stock is at 77 cents! Have a nice day.
"they are out of cash since end of last Qtr."
Not true. Do a little reading, please.
Margin on the LuViva machine is zero, GTHP's only profits come from sales of the disposables. Business model info is on their website. This sale was through a distributor so disposables margin will be lower than if it were a direct sale.